 | • レポートコード：QYR2104Z1842 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、129ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、糖尿病治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（スルホニル尿素剤、ビグアニド剤、メグリチニド剤、チアゾリジンジオン剤、アルファ-グルコシダーゼ阻害剤、DPP-4阻害剤、SGLT-2阻害剤）、用途別市場規模（診断/クリニック、ICU、在宅医療）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・糖尿病治療の市場動向 ・企業の競争状況、市場シェア ・糖尿病治療の種類別市場規模（スルホニル尿素剤、ビグアニド剤、メグリチニド剤、チアゾリジンジオン剤、アルファ-グルコシダーゼ阻害剤、DPP-4阻害剤、SGLT-2阻害剤） ・糖尿病治療の用途別市場規模（診断/クリニック、ICU、在宅医療） ・糖尿病治療の北米市場規模2016-2027（アメリカ、カナダ） ・糖尿病治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・糖尿病治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・糖尿病治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・糖尿病治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Sanofi、Novo Nordisk、MSD、Astrazeneca、Takeda、Novartis、AbbVie、Eli Lilly、North China Pharmaceutical Group Corporation、Huadong Medicine、Dongbao Pharmaceutical、Hisun Pharmacy、KELUN、Ginwa、Tianan Pharmaceutical、Jumpcan Pharmacy、Guangzhou Baiyun Mountain、SHIJIAZHUANG YILING PHARMACEUTICAL、Wanbang Biopharmaceuticals、Gan & Lee、Taloph） ・結論 |
The global diabetic therapeutic market is growing at a high pace owing to the increase in the prevalence of diabetes globally. The top countries with high prevalence of diabetes are China, India, the US, Brazil, Russia, Mexico, Indonesia, Egypt, Japan, and Bangladesh. It is estimated that more than 1.5 million deaths occur due to diabetes worldwide each year.
The report identifies the increasing focus on the self-management of diabetes to be one of the major factors that will have a positive impact on the growth of this market in the coming years. With the recent years witnessing an increase in number of people diagnosed with type 1 diabetes, there has been considerable increase in the adoption of insulin delivery systems. Focusing on skipping the need to schedule appointments and reduce expenses for clinical visits, increases the adoption of insulin delivery systems, where individuals use insulin injections at home under the guidance of a physician. This led to the introduction of insulin pens, pumps, and jet injectors, which, in turn, will drive the growth of the diabetic therapeutics market.
Market Analysis and Insights: Global Diabetic Therapeutic Market
The global Diabetic Therapeutic market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Diabetic Therapeutic market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Diabetic Therapeutic market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Diabetic Therapeutic market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Diabetic Therapeutic market.
Global Diabetic Therapeutic Scope and Market Size
Diabetic Therapeutic market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Diabetic Therapeutic market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Sulphonylureas
Biguanides
Meglitinides
Thiazolidinediones
Alpha-glucosidase Inhibitors
DPP-4 Inhibitors
SGLT-2 Inhibitors
Segment by Application
Diagnostic/Clinics
ICUs
Home Healthcare
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Sanofi
Novo Nordisk
MSD
Astrazeneca
Takeda
Novartis
AbbVie
Eli Lilly
North China Pharmaceutical Group Corporation
Astrazeneca
Takeda
Hisun Pharmacy
KELUN
Ginwa
Tianan Pharmaceutical
Jumpcan Pharmacy
Guangzhou Baiyun Mountain
SHIJIAZHUANG YILING PHARMACEUTICAL
Wanbang Biopharmaceuticals
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Diabetic Therapeutic Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Sulphonylureas
1.2.3 Biguanides
1.2.4 Meglitinides
1.2.5 Thiazolidinediones
1.2.6 Alpha-glucosidase Inhibitors
1.2.7 DPP-4 Inhibitors
1.2.8 SGLT-2 Inhibitors
1.3 Market by Application
1.3.1 Global Diabetic Therapeutic Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Diagnostic/Clinics
1.3.3 ICUs
1.3.4 Home Healthcare
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Diabetic Therapeutic Market Perspective (2016-2027)
2.2 Diabetic Therapeutic Growth Trends by Regions
2.2.1 Diabetic Therapeutic Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Diabetic Therapeutic Historic Market Share by Regions (2016-2021)
2.2.3 Diabetic Therapeutic Forecasted Market Size by Regions (2022-2027)
2.3 Diabetic Therapeutic Industry Dynamic
2.3.1 Diabetic Therapeutic Market Trends
2.3.2 Diabetic Therapeutic Market Drivers
2.3.3 Diabetic Therapeutic Market Challenges
2.3.4 Diabetic Therapeutic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Diabetic Therapeutic Players by Revenue
3.1.1 Global Top Diabetic Therapeutic Players by Revenue (2016-2021)
3.1.2 Global Diabetic Therapeutic Revenue Market Share by Players (2016-2021)
3.2 Global Diabetic Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Diabetic Therapeutic Revenue
3.4 Global Diabetic Therapeutic Market Concentration Ratio
3.4.1 Global Diabetic Therapeutic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Diabetic Therapeutic Revenue in 2020
3.5 Diabetic Therapeutic Key Players Head office and Area Served
3.6 Key Players Diabetic Therapeutic Product Solution and Service
3.7 Date of Enter into Diabetic Therapeutic Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Diabetic Therapeutic Breakdown Data by Type
4.1 Global Diabetic Therapeutic Historic Market Size by Type (2016-2021)
4.2 Global Diabetic Therapeutic Forecasted Market Size by Type (2022-2027)
5 Diabetic Therapeutic Breakdown Data by Application
5.1 Global Diabetic Therapeutic Historic Market Size by Application (2016-2021)
5.2 Global Diabetic Therapeutic Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Diabetic Therapeutic Market Size (2016-2027)
6.2 North America Diabetic Therapeutic Market Size by Type
6.2.1 North America Diabetic Therapeutic Market Size by Type (2016-2021)
6.2.2 North America Diabetic Therapeutic Market Size by Type (2022-2027)
6.2.3 North America Diabetic Therapeutic Market Size by Type (2016-2027)
6.3 North America Diabetic Therapeutic Market Size by Application
6.3.1 North America Diabetic Therapeutic Market Size by Application (2016-2021)
6.3.2 North America Diabetic Therapeutic Market Size by Application (2022-2027)
6.3.3 North America Diabetic Therapeutic Market Size by Application (2016-2027)
6.4 North America Diabetic Therapeutic Market Size by Country
6.4.1 North America Diabetic Therapeutic Market Size by Country (2016-2021)
6.4.2 North America Diabetic Therapeutic Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Diabetic Therapeutic Market Size (2016-2027)
7.2 Europe Diabetic Therapeutic Market Size by Type
7.2.1 Europe Diabetic Therapeutic Market Size by Type (2016-2021)
7.2.2 Europe Diabetic Therapeutic Market Size by Type (2022-2027)
7.2.3 Europe Diabetic Therapeutic Market Size by Type (2016-2027)
7.3 Europe Diabetic Therapeutic Market Size by Application
7.3.1 Europe Diabetic Therapeutic Market Size by Application (2016-2021)
7.3.2 Europe Diabetic Therapeutic Market Size by Application (2022-2027)
7.3.3 Europe Diabetic Therapeutic Market Size by Application (2016-2027)
7.4 Europe Diabetic Therapeutic Market Size by Country
7.4.1 Europe Diabetic Therapeutic Market Size by Country (2016-2021)
7.4.2 Europe Diabetic Therapeutic Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Diabetic Therapeutic Market Size (2016-2027)
8.2 Asia-Pacific Diabetic Therapeutic Market Size by Type
8.2.1 Asia-Pacific Diabetic Therapeutic Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Diabetic Therapeutic Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Diabetic Therapeutic Market Size by Type (2016-2027)
8.3 Asia-Pacific Diabetic Therapeutic Market Size by Application
8.3.1 Asia-Pacific Diabetic Therapeutic Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Diabetic Therapeutic Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Diabetic Therapeutic Market Size by Application (2016-2027)
8.4 Asia-Pacific Diabetic Therapeutic Market Size by Region
8.4.1 Asia-Pacific Diabetic Therapeutic Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Diabetic Therapeutic Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Diabetic Therapeutic Market Size (2016-2027)
9.2 Latin America Diabetic Therapeutic Market Size by Type
9.2.1 Latin America Diabetic Therapeutic Market Size by Type (2016-2021)
9.2.2 Latin America Diabetic Therapeutic Market Size by Type (2022-2027)
9.2.3 Latin America Diabetic Therapeutic Market Size by Type (2016-2027)
9.3 Latin America Diabetic Therapeutic Market Size by Application
9.3.1 Latin America Diabetic Therapeutic Market Size by Application (2016-2021)
9.3.2 Latin America Diabetic Therapeutic Market Size by Application (2022-2027)
9.3.3 Latin America Diabetic Therapeutic Market Size by Application (2016-2027)
9.4 Latin America Diabetic Therapeutic Market Size by Country
9.4.1 Latin America Diabetic Therapeutic Market Size by Country (2016-2021)
9.4.2 Latin America Diabetic Therapeutic Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Diabetic Therapeutic Market Size (2016-2027)
10.2 Middle East & Africa Diabetic Therapeutic Market Size by Type
10.2.1 Middle East & Africa Diabetic Therapeutic Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Diabetic Therapeutic Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Diabetic Therapeutic Market Size by Type (2016-2027)
10.3 Middle East & Africa Diabetic Therapeutic Market Size by Application
10.3.1 Middle East & Africa Diabetic Therapeutic Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Diabetic Therapeutic Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Diabetic Therapeutic Market Size by Application (2016-2027)
10.4 Middle East & Africa Diabetic Therapeutic Market Size by Country
10.4.1 Middle East & Africa Diabetic Therapeutic Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Diabetic Therapeutic Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Details
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Diabetic Therapeutic Introduction
11.1.4 Sanofi Revenue in Diabetic Therapeutic Business (2016-2021)
11.1.5 Sanofi Recent Development
11.2 Novo Nordisk
11.2.1 Novo Nordisk Company Details
11.2.2 Novo Nordisk Business Overview
11.2.3 Novo Nordisk Diabetic Therapeutic Introduction
11.2.4 Novo Nordisk Revenue in Diabetic Therapeutic Business (2016-2021)
11.2.5 Novo Nordisk Recent Development
11.3 MSD
11.3.1 MSD Company Details
11.3.2 MSD Business Overview
11.3.3 MSD Diabetic Therapeutic Introduction
11.3.4 MSD Revenue in Diabetic Therapeutic Business (2016-2021)
11.3.5 MSD Recent Development
11.4 Astrazeneca
11.4.1 Astrazeneca Company Details
11.4.2 Astrazeneca Business Overview
11.4.3 Astrazeneca Diabetic Therapeutic Introduction
11.4.4 Astrazeneca Revenue in Diabetic Therapeutic Business (2016-2021)
11.4.5 Astrazeneca Recent Development
11.5 Takeda
11.5.1 Takeda Company Details
11.5.2 Takeda Business Overview
11.5.3 Takeda Diabetic Therapeutic Introduction
11.5.4 Takeda Revenue in Diabetic Therapeutic Business (2016-2021)
11.5.5 Takeda Recent Development
11.6 Novartis
11.6.1 Novartis Company Details
11.6.2 Novartis Business Overview
11.6.3 Novartis Diabetic Therapeutic Introduction
11.6.4 Novartis Revenue in Diabetic Therapeutic Business (2016-2021)
11.6.5 Novartis Recent Development
11.7 AbbVie
11.7.1 AbbVie Company Details
11.7.2 AbbVie Business Overview
11.7.3 AbbVie Diabetic Therapeutic Introduction
11.7.4 AbbVie Revenue in Diabetic Therapeutic Business (2016-2021)
11.7.5 AbbVie Recent Development
11.8 Eli Lilly
11.8.1 Eli Lilly Company Details
11.8.2 Eli Lilly Business Overview
11.8.3 Eli Lilly Diabetic Therapeutic Introduction
11.8.4 Eli Lilly Revenue in Diabetic Therapeutic Business (2016-2021)
11.8.5 Eli Lilly Recent Development
11.9 North China Pharmaceutical Group Corporation
11.9.1 North China Pharmaceutical Group Corporation Company Details
11.9.2 North China Pharmaceutical Group Corporation Business Overview
11.9.3 North China Pharmaceutical Group Corporation Diabetic Therapeutic Introduction
11.9.4 North China Pharmaceutical Group Corporation Revenue in Diabetic Therapeutic Business (2016-2021)
11.9.5 North China Pharmaceutical Group Corporation Recent Development
11.10 Huadong Medicine
11.10.1 Huadong Medicine Company Details
11.10.2 Huadong Medicine Business Overview
11.10.3 Huadong Medicine Diabetic Therapeutic Introduction
11.10.4 Huadong Medicine Revenue in Diabetic Therapeutic Business (2016-2021)
11.10.5 Huadong Medicine Recent Development
11.11 Dongbao Pharmaceutical
11.11.1 Dongbao Pharmaceutical Company Details
11.11.2 Dongbao Pharmaceutical Business Overview
11.11.3 Dongbao Pharmaceutical Diabetic Therapeutic Introduction
11.11.4 Dongbao Pharmaceutical Revenue in Diabetic Therapeutic Business (2016-2021)
11.11.5 Dongbao Pharmaceutical Recent Development
11.12 Hisun Pharmacy
11.12.1 Hisun Pharmacy Company Details
11.12.2 Hisun Pharmacy Business Overview
11.12.3 Hisun Pharmacy Diabetic Therapeutic Introduction
11.12.4 Hisun Pharmacy Revenue in Diabetic Therapeutic Business (2016-2021)
11.12.5 Hisun Pharmacy Recent Development
11.13 KELUN
11.13.1 KELUN Company Details
11.13.2 KELUN Business Overview
11.13.3 KELUN Diabetic Therapeutic Introduction
11.13.4 KELUN Revenue in Diabetic Therapeutic Business (2016-2021)
11.13.5 KELUN Recent Development
11.14 Ginwa
11.14.1 Ginwa Company Details
11.14.2 Ginwa Business Overview
11.14.3 Ginwa Diabetic Therapeutic Introduction
11.14.4 Ginwa Revenue in Diabetic Therapeutic Business (2016-2021)
11.14.5 Ginwa Recent Development
11.15 Tianan Pharmaceutical
11.15.1 Tianan Pharmaceutical Company Details
11.15.2 Tianan Pharmaceutical Business Overview
11.15.3 Tianan Pharmaceutical Diabetic Therapeutic Introduction
11.15.4 Tianan Pharmaceutical Revenue in Diabetic Therapeutic Business (2016-2021)
11.15.5 Tianan Pharmaceutical Recent Development
11.16 Jumpcan Pharmacy
11.16.1 Jumpcan Pharmacy Company Details
11.16.2 Jumpcan Pharmacy Business Overview
11.16.3 Jumpcan Pharmacy Diabetic Therapeutic Introduction
11.16.4 Jumpcan Pharmacy Revenue in Diabetic Therapeutic Business (2016-2021)
11.16.5 Jumpcan Pharmacy Recent Development
11.17 Guangzhou Baiyun Mountain
11.17.1 Guangzhou Baiyun Mountain Company Details
11.17.2 Guangzhou Baiyun Mountain Business Overview
11.17.3 Guangzhou Baiyun Mountain Diabetic Therapeutic Introduction
11.17.4 Guangzhou Baiyun Mountain Revenue in Diabetic Therapeutic Business (2016-2021)
11.17.5 Guangzhou Baiyun Mountain Recent Development
11.18 SHIJIAZHUANG YILING PHARMACEUTICAL
11.18.1 SHIJIAZHUANG YILING PHARMACEUTICAL Company Details
11.18.2 SHIJIAZHUANG YILING PHARMACEUTICAL Business Overview
11.18.3 SHIJIAZHUANG YILING PHARMACEUTICAL Diabetic Therapeutic Introduction
11.18.4 SHIJIAZHUANG YILING PHARMACEUTICAL Revenue in Diabetic Therapeutic Business (2016-2021)
11.18.5 SHIJIAZHUANG YILING PHARMACEUTICAL Recent Development
11.18 Wanbang Biopharmaceuticals
.1 Wanbang Biopharmaceuticals Company Details
.2 Wanbang Biopharmaceuticals Business Overview
.3 Wanbang Biopharmaceuticals Diabetic Therapeutic Introduction
.4 Wanbang Biopharmaceuticals Revenue in Diabetic Therapeutic Business (2016-2021)
.5 Wanbang Biopharmaceuticals Recent Development
11.20 Gan & Lee
11.20.1 Gan & Lee Company Details
11.20.2 Gan & Lee Business Overview
11.20.3 Gan & Lee Diabetic Therapeutic Introduction
11.20.4 Gan & Lee Revenue in Diabetic Therapeutic Business (2016-2021)
11.20.5 Gan & Lee Recent Development
11.21 Taloph
11.21.1 Taloph Company Details
11.21.2 Taloph Business Overview
11.21.3 Taloph Diabetic Therapeutic Introduction
11.21.4 Taloph Revenue in Diabetic Therapeutic Business (2016-2021)
11.21.5 Taloph Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Diabetic Therapeutic Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Sulphonylureas
Table 3. Key Players of Biguanides
Table 4. Key Players of Meglitinides
Table 5. Key Players of Thiazolidinediones
Table 6. Key Players of Alpha-glucosidase Inhibitors
Table 7. Key Players of DPP-4 Inhibitors
Table 8. Key Players of SGLT-2 Inhibitors
Table 9. Global Diabetic Therapeutic Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 10. Global Diabetic Therapeutic Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 11. Global Diabetic Therapeutic Market Size by Regions (2016-2021) & (US$ Million)
Table 12. Global Diabetic Therapeutic Market Share by Regions (2016-2021)
Table 13. Global Diabetic Therapeutic Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 14. Global Diabetic Therapeutic Market Share by Regions (2022-2027)
Table 15. Diabetic Therapeutic Market Trends
Table 16. Diabetic Therapeutic Market Drivers
Table 17. Diabetic Therapeutic Market Challenges
Table 18. Diabetic Therapeutic Market Restraints
Table 19. Global Diabetic Therapeutic Revenue by Players (2016-2021) & (US$ Million)
Table 20. Global Diabetic Therapeutic Market Share by Players (2016-2021)
Table 21. Global Top Diabetic Therapeutic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Diabetic Therapeutic as of 2020)
Table 22. Ranking of Global Top Diabetic Therapeutic Companies by Revenue (US$ Million) in 2020
Table 23. Global 5 Largest Players Market Share by Diabetic Therapeutic Revenue (CR5 and HHI) & (2016-2021)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Diabetic Therapeutic Product Solution and Service
Table 26. Date of Enter into Diabetic Therapeutic Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Diabetic Therapeutic Market Size by Type (2016-2021) (US$ Million)
Table 29. Global Diabetic Therapeutic Revenue Market Share by Type (2016-2021)
Table 30. Global Diabetic Therapeutic Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 31. Global Diabetic Therapeutic Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 32. Global Diabetic Therapeutic Market Size Share by Application (2016-2021) & (US$ Million)
Table 33. Global Diabetic Therapeutic Revenue Market Share by Application (2016-2021)
Table 34. Global Diabetic Therapeutic Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 35. Global Diabetic Therapeutic Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 36. North America Diabetic Therapeutic Market Size by Type (2016-2021) (US$ Million)
Table 37. North America Diabetic Therapeutic Market Size by Type (2022-2027) & (US$ Million)
Table 38. North America Diabetic Therapeutic Market Size by Application (2016-2021) (US$ Million)
Table 39. North America Diabetic Therapeutic Market Size by Application (2022-2027) & (US$ Million)
Table 40. North America Diabetic Therapeutic Market Size by Country (2016-2021) & (US$ Million)
Table 41. North America Diabetic Therapeutic Market Size by Country (2022-2027) & (US$ Million)
Table 42. Europe Diabetic Therapeutic Market Size by Type (2016-2021) (US$ Million)
Table 43. Europe Diabetic Therapeutic Market Size by Type (2022-2027) & (US$ Million)
Table 44. Europe Diabetic Therapeutic Market Size by Application (2016-2021) (US$ Million)
Table 45. Europe Diabetic Therapeutic Market Size by Application (2022-2027) & (US$ Million)
Table 46. Europe Diabetic Therapeutic Market Size by Country (2016-2021) & (US$ Million)
Table 47. Europe Diabetic Therapeutic Market Size by Country (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Diabetic Therapeutic Market Size by Type (2016-2021) (US$ Million)
Table 49. Asia-Pacific Diabetic Therapeutic Market Size by Type (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Diabetic Therapeutic Market Size by Application (2016-2021) (US$ Million)
Table 51. Asia-Pacific Diabetic Therapeutic Market Size by Application (2022-2027) & (US$ Million)
Table 52. Asia-Pacific Diabetic Therapeutic Market Size by Region (2016-2021) & (US$ Million)
Table 53. Asia-Pacific Diabetic Therapeutic Market Size by Region (2022-2027) & (US$ Million)
Table 54. Latin America Diabetic Therapeutic Market Size by Type (2016-2021) (US$ Million)
Table 55. Latin America Diabetic Therapeutic Market Size by Type (2022-2027) & (US$ Million)
Table 56. Latin America Diabetic Therapeutic Market Size by Application (2016-2021) (US$ Million)
Table 57. Latin America Diabetic Therapeutic Market Size by Application (2022-2027) & (US$ Million)
Table 58. Latin America Diabetic Therapeutic Market Size by Country (2016-2021) & (US$ Million)
Table 59. Latin America Diabetic Therapeutic Market Size by Country (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Diabetic Therapeutic Market Size by Type (2016-2021) (US$ Million)
Table 61. Middle East & Africa Diabetic Therapeutic Market Size by Type (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Diabetic Therapeutic Market Size by Application (2016-2021) (US$ Million)
Table 63. Middle East & Africa Diabetic Therapeutic Market Size by Application (2022-2027) & (US$ Million)
Table 64. Middle East & Africa Diabetic Therapeutic Market Size by Country (2016-2021) & (US$ Million)
Table 65. Middle East & Africa Diabetic Therapeutic Market Size by Country (2022-2027) & (US$ Million)
Table 66. Sanofi Company Details
Table 67. Sanofi Business Overview
Table 68. Sanofi Diabetic Therapeutic Product
Table 69. Sanofi Revenue in Diabetic Therapeutic Business (2016-2021) & (US$ Million)
Table 70. Sanofi Recent Development
Table 71. Novo Nordisk Company Details
Table 72. Novo Nordisk Business Overview
Table 73. Novo Nordisk Diabetic Therapeutic Product
Table 74. Novo Nordisk Revenue in Diabetic Therapeutic Business (2016-2021) & (US$ Million)
Table 75. Novo Nordisk Recent Development
Table 76. MSD Company Details
Table 77. MSD Business Overview
Table 78. MSD Diabetic Therapeutic Product
Table 79. MSD Revenue in Diabetic Therapeutic Business (2016-2021) & (US$ Million)
Table 80. MSD Recent Development
Table 81. Astrazeneca Company Details
Table 82. Astrazeneca Business Overview
Table 83. Astrazeneca Diabetic Therapeutic Product
Table 84. Astrazeneca Revenue in Diabetic Therapeutic Business (2016-2021) & (US$ Million)
Table 85. Astrazeneca Recent Development
Table 86. Takeda Company Details
Table 87. Takeda Business Overview
Table 88. Takeda Diabetic Therapeutic Product
Table 89. Takeda Revenue in Diabetic Therapeutic Business (2016-2021) & (US$ Million)
Table 90. Takeda Recent Development
Table 91. Novartis Company Details
Table 92. Novartis Business Overview
Table 93. Novartis Diabetic Therapeutic Product
Table 94. Novartis Revenue in Diabetic Therapeutic Business (2016-2021) & (US$ Million)
Table 95. Novartis Recent Development
Table 96. AbbVie Company Details
Table 97. AbbVie Business Overview
Table 98. AbbVie Diabetic Therapeutic Product
Table 99. AbbVie Revenue in Diabetic Therapeutic Business (2016-2021) & (US$ Million)
Table 100. AbbVie Recent Development
Table 101. Eli Lilly Company Details
Table 102. Eli Lilly Business Overview
Table 103. Eli Lilly Revenue in Diabetic Therapeutic Business (2016-2021) & (US$ Million)
Table 104. Eli Lilly Recent Development
Table 105. North China Pharmaceutical Group Corporation Company Details
Table 106. North China Pharmaceutical Group Corporation Business Overview
Table 107. North China Pharmaceutical Group Corporation Diabetic Therapeutic Product
Table 108. North China Pharmaceutical Group Corporation Revenue in Diabetic Therapeutic Business (2016-2021) & (US$ Million)
Table 109. North China Pharmaceutical Group Corporation Recent Development
Table 110. Huadong Medicine Company Details
Table 111. Huadong Medicine Business Overview
Table 112. Huadong Medicine Diabetic Therapeutic Product
Table 113. Huadong Medicine Revenue in Diabetic Therapeutic Business (2016-2021) & (US$ Million)
Table 114. Huadong Medicine Recent Development
Table 115. Dongbao Pharmaceutical Company Details
Table 116. Dongbao Pharmaceutical Business Overview
Table 117. Dongbao Pharmaceutical Diabetic Therapeutic Product
Table 118. Dongbao Pharmaceutical Revenue in Diabetic Therapeutic Business (2016-2021) & (US$ Million)
Table 119. Dongbao Pharmaceutical Recent Development
Table 120. Hisun Pharmacy Company Details
Table 121. Hisun Pharmacy Business Overview
Table 122. Hisun Pharmacy Diabetic Therapeutic Product
Table 123. Hisun Pharmacy Revenue in Diabetic Therapeutic Business (2016-2021) & (US$ Million)
Table 124. Hisun Pharmacy Recent Development
Table 125. KELUN Company Details
Table 126. KELUN Business Overview
Table 127. KELUN Diabetic Therapeutic Product
Table 128. KELUN Revenue in Diabetic Therapeutic Business (2016-2021) & (US$ Million)
Table 129. KELUN Recent Development
Table 130. Ginwa Company Details
Table 131. Ginwa Business Overview
Table 132. Ginwa Diabetic Therapeutic Product
Table 133. Ginwa Revenue in Diabetic Therapeutic Business (2016-2021) & (US$ Million)
Table 134. Ginwa Recent Development
Table 135. Tianan Pharmaceutical Company Details
Table 136. Tianan Pharmaceutical Business Overview
Table 137. Tianan Pharmaceutical Diabetic Therapeutic Product
Table 138. Tianan Pharmaceutical Revenue in Diabetic Therapeutic Business (2016-2021) & (US$ Million)
Table 139. Tianan Pharmaceutical Recent Development
Table 140. Jumpcan Pharmacy Company Details
Table 141. Jumpcan Pharmacy Business Overview
Table 142. Jumpcan Pharmacy Diabetic Therapeutic Product
Table 143. Jumpcan Pharmacy Revenue in Diabetic Therapeutic Business (2016-2021) & (US$ Million)
Table 144. Jumpcan Pharmacy Recent Development
Table 145. Guangzhou Baiyun Mountain Company Details
Table 146. Guangzhou Baiyun Mountain Business Overview
Table 147. Guangzhou Baiyun Mountain Diabetic Therapeutic Product
Table 148. Guangzhou Baiyun Mountain Revenue in Diabetic Therapeutic Business (2016-2021) & (US$ Million)
Table 149. Guangzhou Baiyun Mountain Recent Development
Table 150. SHIJIAZHUANG YILING PHARMACEUTICAL Company Details
Table 151. SHIJIAZHUANG YILING PHARMACEUTICAL Business Overview
Table 152. SHIJIAZHUANG YILING PHARMACEUTICAL Diabetic Therapeutic Product
Table 153. SHIJIAZHUANG YILING PHARMACEUTICAL Revenue in Diabetic Therapeutic Business (2016-2021) & (US$ Million)
Table 154. SHIJIAZHUANG YILING PHARMACEUTICAL Recent Development
Table 155. Wanbang Biopharmaceuticals Company Details
Table 156. Wanbang Biopharmaceuticals Business Overview
Table 157. Wanbang Biopharmaceuticals Diabetic Therapeutic Product
Table 158. Wanbang Biopharmaceuticals Revenue in Diabetic Therapeutic Business (2016-2021) & (US$ Million)
Table 159. Wanbang Biopharmaceuticals Recent Development
Table 160. Gan & Lee Company Details
Table 161. Gan & Lee Business Overview
Table 162. Gan & Lee Diabetic Therapeutic Product
Table 163. Gan & Lee Revenue in Diabetic Therapeutic Business (2016-2021) & (US$ Million)
Table 164. Gan & Lee Recent Development
Table 165. Taloph Company Details
Table 166. Taloph Business Overview
Table 167. Taloph Diabetic Therapeutic Product
Table 168. Taloph Revenue in Diabetic Therapeutic Business (2016-2021) & (US$ Million)
Table 169. Taloph Recent Development
Table 170. Research Programs/Design for This Report
Table 171. Key Data Information from Secondary Sources
Table 172. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Diabetic Therapeutic Market Share by Type: 2020 VS 2027
Figure 2. Sulphonylureas Features
Figure 3. Biguanides Features
Figure 4. Meglitinides Features
Figure 5. Thiazolidinediones Features
Figure 6. Alpha-glucosidase Inhibitors Features
Figure 7. DPP-4 Inhibitors Features
Figure 8. SGLT-2 Inhibitors Features
Figure 9. Global Diabetic Therapeutic Market Share by Application: 2020 VS 2027
Figure 10. Diagnostic/Clinics Case Studies
Figure 11. ICUs Case Studies
Figure 12. Home Healthcare Case Studies
Figure 13. Diabetic Therapeutic Report Years Considered
Figure 14. Global Diabetic Therapeutic Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 15. Global Diabetic Therapeutic Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 16. Global Diabetic Therapeutic Market Share by Regions: 2020 VS 2027
Figure 17. Global Diabetic Therapeutic Market Share by Regions (2022-2027)
Figure 18. Global Diabetic Therapeutic Market Share by Players in 2020
Figure 19. Global Top Diabetic Therapeutic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Diabetic Therapeutic as of 2020
Figure 20. The Top 10 and 5 Players Market Share by Diabetic Therapeutic Revenue in 2020
Figure 21. Global Diabetic Therapeutic Revenue Market Share by Type (2016-2021)
Figure 22. Global Diabetic Therapeutic Revenue Market Share by Type (2022-2027)
Figure 23. North America Diabetic Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. North America Diabetic Therapeutic Market Share by Type (2016-2027)
Figure 25. North America Diabetic Therapeutic Market Share by Application (2016-2027)
Figure 26. North America Diabetic Therapeutic Market Share by Country (2016-2027)
Figure 27. United States Diabetic Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Canada Diabetic Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Diabetic Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Europe Diabetic Therapeutic Market Share by Type (2016-2027)
Figure 31. Europe Diabetic Therapeutic Market Share by Application (2016-2027)
Figure 32. Europe Diabetic Therapeutic Market Share by Country (2016-2027)
Figure 33. Germany Diabetic Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. France Diabetic Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. U.K. Diabetic Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Italy Diabetic Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Russia Diabetic Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Nordic Diabetic Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Diabetic Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Asia-Pacific Diabetic Therapeutic Market Share by Type (2016-2027)
Figure 41. Asia-Pacific Diabetic Therapeutic Market Share by Application (2016-2027)
Figure 42. Asia-Pacific Diabetic Therapeutic Market Share by Region (2016-2027)
Figure 43. China Diabetic Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Japan Diabetic Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. South Korea Diabetic Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Southeast Asia Diabetic Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. India Diabetic Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Australia Diabetic Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Diabetic Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Latin America Diabetic Therapeutic Market Share by Type (2016-2027)
Figure 51. Latin America Diabetic Therapeutic Market Share by Application (2016-2027)
Figure 52. Latin America Diabetic Therapeutic Market Share by Country (2016-2027)
Figure 53. Mexico Diabetic Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Brazil Diabetic Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Diabetic Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Middle East & Africa Diabetic Therapeutic Market Share by Type (2016-2027)
Figure 57. Middle East & Africa Diabetic Therapeutic Market Share by Application (2016-2027)
Figure 58. Middle East & Africa Diabetic Therapeutic Market Share by Country (2016-2027)
Figure 59. Turkey Diabetic Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Saudi Arabia Diabetic Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. UAE Diabetic Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. Sanofi Revenue Growth Rate in Diabetic Therapeutic Business (2016-2021)
Figure 63. Novo Nordisk Revenue Growth Rate in Diabetic Therapeutic Business (2016-2021)
Figure 64. MSD Revenue Growth Rate in Diabetic Therapeutic Business (2016-2021)
Figure 65. Astrazeneca Revenue Growth Rate in Diabetic Therapeutic Business (2016-2021)
Figure 66. Takeda Revenue Growth Rate in Diabetic Therapeutic Business (2016-2021)
Figure 67. Novartis Revenue Growth Rate in Diabetic Therapeutic Business (2016-2021)
Figure 68. AbbVie Revenue Growth Rate in Diabetic Therapeutic Business (2016-2021)
Figure 69. Eli Lilly Revenue Growth Rate in Diabetic Therapeutic Business (2016-2021)
Figure 70. North China Pharmaceutical Group Corporation Revenue Growth Rate in Diabetic Therapeutic Business (2016-2021)
Figure 71. Huadong Medicine Revenue Growth Rate in Diabetic Therapeutic Business (2016-2021)
Figure 72. Dongbao Pharmaceutical Revenue Growth Rate in Diabetic Therapeutic Business (2016-2021)
Figure 73. Hisun Pharmacy Revenue Growth Rate in Diabetic Therapeutic Business (2016-2021)
Figure 74. KELUN Revenue Growth Rate in Diabetic Therapeutic Business (2016-2021)
Figure 75. Ginwa Revenue Growth Rate in Diabetic Therapeutic Business (2016-2021)
Figure 76. Tianan Pharmaceutical Revenue Growth Rate in Diabetic Therapeutic Business (2016-2021)
Figure 77. Jumpcan Pharmacy Revenue Growth Rate in Diabetic Therapeutic Business (2016-2021)
Figure 78. Guangzhou Baiyun Mountain Revenue Growth Rate in Diabetic Therapeutic Business (2016-2021)
Figure 79. SHIJIAZHUANG YILING PHARMACEUTICAL Revenue Growth Rate in Diabetic Therapeutic Business (2016-2021)
Figure 80. Wanbang Biopharmaceuticals Revenue Growth Rate in Diabetic Therapeutic Business (2016-2021)
Figure 81. Gan & Lee Revenue Growth Rate in Diabetic Therapeutic Business (2016-2021)
Figure 82. Taloph Revenue Growth Rate in Diabetic Therapeutic Business (2016-2021)
Figure 83. Bottom-up and Top-down Approaches for This Report
Figure 84. Data Triangulation
Figure 85. Key Executives Interviewed
世界の抗糖尿病薬市場規模・現状・予測（2021年-2027年） The anti-diabetics market includes drugs, which are used for treatment of diabetes mellitus and are also known as oral hypoglycemic/antihyperglycemic agents. The anti-diabetics market has grown tremendously in recent years with increasing prevalence of diabetes mellitus. Thus, systemic therapies for…- 世界の抗糖尿病薬市場規模・現状・予測（2021年-2027年） The anti-diabetics market includes drugs, which are used for treatment of diabetes mellitus and are also known as oral hypoglycemic/antihyperglycemic agents. The anti-diabetics market has grown tremendously in recent years with increasing prevalence of diabetes mellitus. Thus, systemic therapies for…
- 世界の糖尿病性腎症市場規模・現状・予測（2021年-2027年） Diabetic nephropathy is a disease of the kidney glomerulus and one of the most significant complications in terms of mortality and morbidity for patients with diabetes. Diabetic nephropathy is mainly characterized by macroalbuminuria. The presence of over 300 milligrams of albumin in the urine in 1 …
- 世界の糖尿病性腎症市場規模・現状・予測（2021年-2027年） Diabetic nephropathy is a disease of the kidney glomerulus and one of the most significant complications in terms of mortality and morbidity for patients with diabetes. Diabetic nephropathy is mainly characterized by macroalbuminuria. The presence of over 300 milligrams of albumin in the urine in 1 …
- 世界のTNF阻害剤市場規模・現状・予測（2021年-2027年） TNF (tumor necrosis factor) inhibitors are anti-inflammatory drugs. TNF inhibitors help to block the TNF alpha that occurs naturally in the body and causes inflammation. TNF drugs are used to reduce inflammation and stop disease progression by targeting the tumor necrosis factor, which is an inflamm…